1. Ophthalmic Drug Facts, J. B. Lippincott, New York, 1989, pp. 136–137.
2. C. M. Ellingson, R. D. Schoenwald, C. F. Barfknecht, C. S. Rao, and S. L. Laban. Rapid toxicological model for use in assessing ocular drugs.Biopharm. Drug Dispos.,13:461–480 (1992).
3. S. L. Laban.Chemistry of ophthalmic topical carbonic anhydrase inhibitors, ophthalmic nonsteroidal antiinflammatory agents, and a spiperone-based magnetic resonance image enhancement agent. Ph.D. Thesis, University of Iowa, 1988.
4. C. Hansch. Appendix I. In W. P. Purcell, G. E. Bass, and J. M. Clayton (eds.),Strategy of Drug Design: A Guide to Biological Activity, Wiley, New York, 1973, pp. 126–133.
5. G. Gran. Determination of the equivalent point in potentiometric titrations.Acta Chem. Scand. 4:559–577 (1950).